Replies to post #269 on Techprecision Corp (TPCS)

[The Night Stalker]

TechPrecision Corporation Congratulates Mevion Medical Systems on Delivering First MEVION S250 Proton Therapy System for Trea...
Date : 12/23/2013 @ 8:00AM
Source : PR Newswire (US)
Stock : NO^TPCS (TPCS)
Quote : 0.625 0.0 (0.00%) @ 5:02PM
TechPrecision Corporation Congratulates Mevion Medical Systems on Delivering First MEVION S250 Proton Therapy System for Trea...
Print
Alert
Techprecision Corp. (QB) (USOTC:TPCS)
Historical Stock Chart
1 Month : From Nov 2013 to Dec 2013

Click Here for more Techprecision Corp. (QB) Charts.
CENTER VALLEY, Pa., Dec. 23, 2013 /PRNewswire/ -- TechPrecision Corporation (OTC Bulletin Board: TPCS) ("TechPrecision" or "the Company"), an industry leading global manufacturer of precision, large-scale fabricated and machined metal components and tested systems with customers in the naval/maritime, energy and precision industrial sectors, today congratulated Mevion Medical Systems on the milestone event of delivering the world's first MEVION S250 Proton Therapy System for treatment at the S. Lee Kling Proton Therapy Center at Barnes-Jewish Hospital in St. Louis. A patient with a rare type of cancer called chondrosarcoma at the base of the skull has become the first person in the world to receive proton therapy using the system.

The MEVION S250 is a unique proton therapy device designed to deliver highly precise doses of radiation while limiting unnecessary radiation to healthy tissue. TechPrecision has partnered with Mevion Systems since 2006 helping to develop for the innovative, low cost and smaller proton beam radiotherapy solution for treating tumors. In January 2013, TechPrecision announced a five-year agreement with Mevion to exclusively produce precision components for their proton beam radiotherapy system.

"This is a critical next step to continuing the rollout of this innovative, cost-effective and precise device which promises to greatly improve the treatment of specific types of cancers," commented Len Anthony, TechPrecision's Executive Chairman. "We are proud of the part TechPrecision has played in delivering this strategic project which will greatly benefit patients and which has been eagerly awaited by the medical community, reflected in the current 11 systems under active development in the U.S. alone. Previously, proton therapy adoption was limited by the high costs of larger conventional systems, but the MEVION S250 system offers significantly lower capital and operating costs, enabling a wider range of facilities to provide proton therapy."

About TechPrecision Corporation

TechPrecision Corporation, through its wholly owned subsidiaries, Ranor, Inc., and Wuxi Critical Mechanical Components Co., Ltd., globally manufactures large-scale, metal fabricated and machined precision components and equipment. These products are used in a variety of markets including: energy, naval/maritime and precision industrial. TechPrecision's goal is to be an end-to-end global service provider to its customers by furnishing customized and integrated "turn-key" solutions for completed products requiring custom fabrication and machining, assembly, inspection and testing. To learn more about the Company, please visit the corporate website at http://www.techprecision.com. Information on the Company's website or any other website does not constitute a part of this press release.

[The Night Stalker]

much more upside potential, the milestone was a game changer